Calidi Biotherapeutics, Inc. (CLDI)

NYSEAMERICAN: CLDI · IEX Real-Time Price · USD
0.565
-0.003 (-0.48%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer.

It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors.

The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety.

Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors.

The company was founded in 2014 and is based in San Diego, California.

Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 41
CEO Allan J. Camaisa

Contact Details

Address:
4475 Executive Drive, Suite 200
San Diego, California 92121
United States
Phone 858-794-9600
Website calidibio.com

Stock Details

Ticker Symbol CLDI
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001855485
Employer ID 86-2967193
SIC Code 2836

Key Executives

Name Position
Allan J. Camaisa Chief Executive Officer and Chairman of the Board
Wendy Pizarro Campbell Esq. Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer and Corporate Secretary
Dr. Boris Minev M.D., Ph.D. President of Medical and Scientific Affairs and Interim Chief Medical Officer
Andrew C. Jackson Chief Financial Officer
Dr. Amish Patel Ph.D. Senior Vice President of Technical Operations
Dr. David Sans M.B.A., Ph.D. Chief Corporate Development
Stephen Thesing Chief Business Officer

Latest SEC Filings

Date Type Title
Mar 21, 2024 D Notice of Exempt Offering of Securities
Mar 21, 2024 D Notice of Exempt Offering of Securities
Mar 21, 2024 D Notice of Exempt Offering of Securities
Mar 21, 2024 D Notice of Exempt Offering of Securities
Mar 21, 2024 D Notice of Exempt Offering of Securities
Mar 18, 2024 8-K Current Report
Mar 15, 2024 10-K Annual Report
Mar 12, 2024 424B3 Prospectus
Mar 12, 2024 8-K Current Report
Mar 1, 2024 424B3 Prospectus